[ Back to EurekAlert! ] Public release date: 6-Nov-2007
[ | E-mail Share Share ]

Contact: Mary Kohut
press@plos.org
415-568-3460
Public Library of Science

Gene expression profiling of dengue virus infection in cell lines and patients

Researchers at the Novartis Institute for Tropical Diseases and the Genome Institute of Singapore have identified new host genes associated with dengue virus infection, which may open new avenues to developing a drug to treat the disease.

Dengue is the most prevalent mosquito-born viral disease affecting humans. Dengue-related disease results in an estimated 50-100 million cases of dengue fever and 250,000 to 500,000 cases of dengue hemorrhagic fever/dengue shock syndrome each year. Yet there is, at present, no drug treatment at all for the disease nor are there any validated host targets for therapeutic intervention.

Using microarray technology to monitor the response of virtually every human gene, Dr Subhash Vasudevan and Dr. Martin Hibberd’s team aimed to identify the ways in which humans interact with dengue virus during infection in order to discover new treatment targets that could be exploited to control viral replication.

From the activated genes, the researchers identified three pathways common to in vitro and in vivo infection; the NF-kappaB initiated immune pathway, the type I interferon pathway, and the ubiquitin proteasome pathway. They next found that inhibiting the ubiquitin proteasome pathway, or activating the type I interferon pathway, resulted in significant inhibition of viral replication whereas inhibiting the NF-kappaB initiated immune pathway had no effect on viral replication. These results suggest that drugs that target the host pathways may prove effective against dengue.

###

CITATION: Fink J, Gu F, Ling L, Tolfvenstam T, Olfat F, et al. (2007) Host Gene Expression Profiling of Dengue Virus Infection in Cell Lines and Patients. PLoS Negl Trop Dis 1(2): e86. doi:10.1371/journal.pntd.0000086

MEDIA CONTACT:
Professor Paul L Herrling, PhD
Head of Corporate Research
Novartis International
CH-4002 Basel
SWITZERLAND
+41 61 324 62 84
paul.herrling@novartis.com

PLEASE MENTION THE OPEN-ACCESS JOURNAL PLoS NEGLECTED TROPICAL DISEASES (www.plosntds.org) AS THE SOURCE FOR THIS ARTICLE AND PROVIDE A LINK TO THE FREELY AVAILABLE TEXT. THANK YOU.

PLoS Neglected Tropical Diseases is an open-access, peer-reviewed journal published weekly by the Public Library of Science (PLoS).



[ Back to EurekAlert! ] [ | E-mail Share Share ]

 


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.